🇺🇸 FDA
Patent

US 7312226

Substituted tricyclic compounds as protein kinase inhibitors

granted A61PA61P35/00A61P35/04

Quick answer

US patent 7312226 (Substituted tricyclic compounds as protein kinase inhibitors) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon Dec 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue Dec 25 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 20 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61P, A61P35/00, A61P35/04, A61P43/00